2021年欧洲心力衰竭指南:个体化治疗的案例

IF 3.2 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

European Cardiology Review Pub Date : 2022-01-28 eCollection Date: 2022-02-01 DOI:10.15420/ecr.2021.57

Nesan Shanmugam

{"title":"2021年欧洲心力衰竭指南:个体化治疗的案例","authors":"Nesan Shanmugam","doi":"10.15420/ecr.2021.57","DOIUrl":null,"url":null,"abstract":"© RADCLIFFE CARDIOLOGY 2022 www.ECRjournal.com The field of heart failure (HF) has seen the development of unparalleled evidence-based therapies over the last 30 years, with continuous improvement in survival and quality of life for our patients. It is unquestionably an exciting time to be considering or pursuing HF as a subspecialty. Pivotal to and underpinning these advances is the guidance provided by international HF guidelines, particularly from the European Society of Cardiology (ESC). The new 2021 ESC HF guidelines have a total of 41 new and 15 modified recommendations from the 2016 document.1","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2022-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1c/cb/ecr-17-e01.PMC8819603.pdf","citationCount":"0","resultStr":"{\"title\":\"The 2021 European Heart Failure Guidelines: The Case for Personalised Therapeutics.\",\"authors\":\"Nesan Shanmugam\",\"doi\":\"10.15420/ecr.2021.57\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"© RADCLIFFE CARDIOLOGY 2022 www.ECRjournal.com The field of heart failure (HF) has seen the development of unparalleled evidence-based therapies over the last 30 years, with continuous improvement in survival and quality of life for our patients. It is unquestionably an exciting time to be considering or pursuing HF as a subspecialty. Pivotal to and underpinning these advances is the guidance provided by international HF guidelines, particularly from the European Society of Cardiology (ESC). The new 2021 ESC HF guidelines have a total of 41 new and 15 modified recommendations from the 2016 document.1\",\"PeriodicalId\":45957,\"journal\":{\"name\":\"European Cardiology Review\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2022-01-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1c/cb/ecr-17-e01.PMC8819603.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Cardiology Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15420/ecr.2021.57\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/2/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Cardiology Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15420/ecr.2021.57","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/2/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The 2021 European Heart Failure Guidelines: The Case for Personalised Therapeutics.

© RADCLIFFE CARDIOLOGY 2022 www.ECRjournal.com The field of heart failure (HF) has seen the development of unparalleled evidence-based therapies over the last 30 years, with continuous improvement in survival and quality of life for our patients. It is unquestionably an exciting time to be considering or pursuing HF as a subspecialty. Pivotal to and underpinning these advances is the guidance provided by international HF guidelines, particularly from the European Society of Cardiology (ESC). The new 2021 ESC HF guidelines have a total of 41 new and 15 modified recommendations from the 2016 document.1

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European Cardiology Review CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

5.40

自引率

0.00%

发文量

审稿时长

12 weeks